It remains to be determined if adequate protein consumption and strength-based exercise would ameliorate skeletal muscle mass loss observed with tirzepatide treatment.
there needs to be more research with GLP/dual agonists and diet change/weight training
Patient attempted to titrate up the dose of tirzepatide to 5 mg weekly multiple times, but each time discontinued the higher dose because of gastrointestinal side effects.
what if a patient was not happy with the results because they could not tolerate the higher dose?
dulaglutide and semaglutide but had to discontinue these medications because of gastrointestinal side effects such as nausea and abdominal cramping.
semaglutide side effects being too harmful for the long term
imperative to consume adequate protein
some patients may require diet changes. Appetite suppression from pharmacology should not be the sole reason for weight loss or else there are more negatives
Strength or resistance-based exercises may aid in preserving skeletal muscle mass when using dual-action incretin
in order to prevent muscle loss weight training is important in order to preserve muscle. This may reduce the risk of sarcopenia which is a major contributor to falls/injury in older adults.
serial body composition assessments should be obtained in patients on tirzepatide
it is important to know if the weight loss is a healthy ratio of fat to SM
Muscle mass loss constituted 34% of the total body weight loss.
about 1/3 of weight loss came from muscle
loss of skeletal muscle mass has been well described with the use of glucagon-like peptide 1 receptor agonists, there is little information regarding the effect of dual glucagon-like peptide 1/glucose-dependent insulinotropic polypeptide receptor agonist tirzepatide
researchers want to find if the dual agonists also lead to a loss of skeletal muscle mass